Roche: CHMP Backs Tecentriq in Extensive-Stage Small-Cell Lung Cancer
July 26 2019 - 10:46AM
Dow Jones News
By Colin Kellaher
Roche Holding AG (ROG.EB) on Friday said the European Medicines
Agency's Committee for Medicinal Products for Human Use recommended
approval of the cancer drug Tecentriq in combination with
chemotherapy for the initial treatment of adults with
extensive-stage small-cell lung cancer.
The Swiss drugmaker said the CHMP positive opinion is based on
the results from a Phase 3 study that showed the Tecentriq
combination significantly improved overall survival and
progression-free survival in such patients.
Lung cancer is the leading cause of cancer death worldwide, and
small-cell lung cancer accounts for about 15% of all cases, with
some 70% of patients diagnosed in the "extensive stage," which
often means a poor prognosis, Roche said.
The company said it expects a final decision from the European
Commission in the near future. The commission generally follows the
CHMP's recommendations.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 26, 2019 10:31 ET (14:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024